All the coronavirus vaccines we have are said to surpass WHO safety standards, and have proven to be well-efficacious. But that doesn’t mean that all vaccines are equal, and provide the same level of protection. The benefits and immune protection profiles are similar, but not standard. This means that certain vaccines could be much more suited for someone, or some vaccines could potentially flag off higher risks of breakthroughs. Hence, while it’s important to get jabbed with any vaccine available to you, weighing relative risk reduction, i.e. how much an individual COVID-19 vaccine lessens risk of infection compared to unvaccinated population, is necessary. Also comparable are odds of symptomatic illness, severity, transmission, and other safety profiles.
While there’s ongoing clinical study on the matter, comparative evaluations and real-world data have pointed out that the Modera and Pfizer mRNA vaccines offer a 95% reduction in symptomatic illness, while Jannsen vaccine offered a 60% reduced risk. With the Astrazeneca (Covishield) shot, there is a 70% reduction, which could be scaled up to over 80% if the gap between doses is lengthened.